APGN — Apexigen Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
Brief: Apexigen Says Phase 2 Data Evaluating Sotigalimab, Its CD40 Agonist Antibody, In Combination With Doxorubicin Marked Increases In Overall Survival Observed Across Soft Tissue Sarcoma Patients
Apexigen rises on buyout deal with Pyxis Oncology
Brief: Pyxis Oncology To Acquire Apexigen For Total Enterprise Value Of About $16 Million
Brief: Apexigen Inc Says On April 11, Co Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
Brief: Apexigen To Reduce Workforce, Exploring Sale
Brief: Apexigen Announces Approximately $2.8 Million Private Placement Financing
Apexigen rises on positive data from cancer drug study
Brief: Apexigen Announces New Phase 2 Data Evaluating Sotigalimab, Cd40 Agonist Antibody, At Asco Gastrointestinal Cancers Symposium 2023
Brief: Apexigen Announces Positive Interim Results From Phase 2 Trial
Brief: Apexigen Announces New Data From A Phase 1/2 Trial Evaluating Its Cd40 Antibody, Sotigalimab
U.S. STOCKS ON THE MOVE-Perrigo, FG Financial, Alector
U.S. STOCKS ON THE MOVE-Metal miners, Rambus, Nuwellis
U.S. STOCKS ON THE MOVE-Titan Medical, Gold miners, Relay Therapeutics
Apexigen rises after positive cancer therapy data
Brief: Apexigen Inc Files Prospectus Relates To Offer And Sale From Time To Time Of Up To 17.3 Million Shares Of Common Stock By Lincoln Park Capital Fund, Llc
Brief: Apexigen Inc Files For Primary Offering Of 3.7 Million Shares Of Common Stock Issuable Upon Exercise Of Warrants - SEC Filing
Brief: Apexigen And Brookline Capital Acquisition Corp Announce Effectiveness Of Registration Statement And Annual Stockholder Meeting To Approve The Proposed Business Combination
Brief: Apexigen Says Meenu Karson Appointed To Board As Chair
Brief: Apexigen Appoints William Duke As CFO